JAK2V617F detection and dosage of serum erythropoietin: First steps of the diagnostic work-up for patients consulting for elevated hematocrit

Haematologica

Volumn 92, Issue 3, 2007, Pages 431-432

  Girodon, François ^a,h   Lippert, Eric ^b   Mossuz, Pascal ^c   Dobo, Irène ^d   Boiret Dupré, Nathalie ^e   Lesesve, Jean François ^f   Hermouet, Sylvie ^g   Praloran, Vincent ^b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h HÔPITAL DU BOCAGE   (France)

Author keywords

Erythrocytosis; Erythropoietin; JAK2V617F; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

ERYTHROPOIETIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ERYTHROCYTOSIS; FEMALE; GRANULOCYTE; HEMATOCRIT; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PHLEBOTOMY; POLYCYTHEMIA; POLYMERASE CHAIN REACTION; WORLD HEALTH ORGANIZATION; AMINO ACID SUBSTITUTION; BLOOD; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; ENZYMOLOGY; EVALUATION; GENE FREQUENCY; GENETICS; LETTER; MISSENSE MUTATION; POINT MUTATION; POLYCYTHEMIA VERA; PREDICTION AND FORECASTING;

AMINO ACID SUBSTITUTION; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; ERYTHROPOIETIN; FEMALE; GENE FREQUENCY; HEMATOCRIT; HUMANS; JANUS KINASE 2; MALE; MUTANT PROTEINS; MUTATION, MISSENSE; POINT MUTATION; POLYCYTHEMIA; POLYCYTHEMIA VERA; PREDICTIVE VALUE OF TESTS;

EID: 34247622402     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10660     Document Type: Article

References (10)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
5. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-7.
6. James C, Delhommeau F, Marzac C, Teyssandier I, Couedic JP, Giraudier S, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006;20:350-3.
7. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005; 42: 206-20.
8. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 2006;30:739-44.
9. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89:1194-8.
10. Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica 2006;91:413-4.